Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Prescription Stimulants In College And Medical Students: A Narrative Review Of Misuse, Cognitive Impact, And Adverse Effects, Amber N. Edinoff, Catherine A. Nix, Shawn E. Mcneil, Sarah E. Wagner, Catherine A. Johnson, Brooke C. Williams, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye, Alan David Kaye
Prescription Stimulants In College And Medical Students: A Narrative Review Of Misuse, Cognitive Impact, And Adverse Effects, Amber N. Edinoff, Catherine A. Nix, Shawn E. Mcneil, Sarah E. Wagner, Catherine A. Johnson, Brooke C. Williams, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye, Alan David Kaye
School of Pharmacy Faculty Articles
Stimulants are effective in treating attention-deficit/hyperactivity disorder (ADHD). Psychiatrist Charles Bradley first made this discovery in 1937 when he found that children treated with amphetamines showed improvements in school performance and behavior. Between 1995 and 2008, stimulants to treat ADHD increased six-fold among American adults and adolescents at an annual rate of 6.5%. Stimulants without a prescription, known as nonmedical use or misuse, have also increased. The highest rates of nonmedical prescription drug misuse in the United States are seen most notably in young adults between 18 and 25 years, based on data from the Substance Abuse and Mental Health …
Viloxazine In The Treatment Of Attention Deficit Hyperactivity Disorder, Amber N. Edinoff, Haseeb A. Akuly, John H. Wagner, Megan A. Boudreaux, Leah A. Kaplan, Shadman Yusuf, Elisa E. Neuchat, Elyse M. Cornett, Andrea G. Boyer, Adam M. Kaye, Alan David Kaye
Viloxazine In The Treatment Of Attention Deficit Hyperactivity Disorder, Amber N. Edinoff, Haseeb A. Akuly, John H. Wagner, Megan A. Boudreaux, Leah A. Kaplan, Shadman Yusuf, Elisa E. Neuchat, Elyse M. Cornett, Andrea G. Boyer, Adam M. Kaye, Alan David Kaye
School of Pharmacy Faculty Articles
Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in children. Over the past twenty years, research on the disease and its characteristics and treatment options has grown exponentially. The first-line pharmacologic treatment of ADHD is stimulants, which have a response rate of ~70%. With the support of four phase 3 studies involving more than 1,000 pediatric patients 6–17 years old, the FDA has approved the non-stimulant, serotonin-norepinephrine modulating agent (SNMA) viloxazine in an extended-release capsule (viloxazine ER) for treatment of ADHD in children aged 6–17. Viloxazine modulates serotonergic activity as a selective 5-HT22B receptor antagonist and 5-HT2C …